{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:02:48Z","timestamp":1762254168021,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T00:00:00Z","timestamp":1655510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"funda\u00e7\u00e3o para a ci\u00eancia e a tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/76038\/2011","UID\/BIA\/04050\/2019"],"award-info":[{"award-number":["SFRH\/BD\/76038\/2011","UID\/BIA\/04050\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12032-022-01712-0","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T10:10:46Z","timestamp":1655547046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: implications in cancer therapy"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1754-9254","authenticated-orcid":false,"given":"J.","family":"Azevedo-Silva","sequence":"first","affiliation":[]},{"given":"D.","family":"Tavares-Valente","sequence":"additional","affiliation":[]},{"given":"A.","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"O.","family":"Queir\u00f3s","sequence":"additional","affiliation":[]},{"given":"F.","family":"Baltazar","sequence":"additional","affiliation":[]},{"given":"Y. H.","family":"Ko","sequence":"additional","affiliation":[]},{"given":"P. L.","family":"Pedersen","sequence":"additional","affiliation":[]},{"given":"A.","family":"Preto","sequence":"additional","affiliation":[]},{"given":"M.","family":"Casal","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,6,18]]},"reference":[{"issue":"1","key":"1712_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0304-3835(01)00667-X","volume":"173","author":"YH Ko","year":"2001","unstructured":"Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett. 2001;173(1):83\u201391.","journal-title":"Cancer Lett"},{"issue":"1","key":"1712_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.bbrc.2004.09.047","volume":"324","author":"YH Ko","year":"2004","unstructured":"Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun. 2004;324(1):269\u201375. https:\/\/doi.org\/10.1016\/j.bbrc.2004.09.047.","journal-title":"Biochem Biophys Res Commun"},{"issue":"34","key":"1712_CR3","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1038\/sj.onc.1209603","volume":"25","author":"SP Mathupala","year":"2006","unstructured":"Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer\u2019s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006;25(34):4777\u201386. https:\/\/doi.org\/10.1038\/sj.onc.1209603.","journal-title":"Oncogene"},{"issue":"12","key":"1712_CR4","first-page":"4909","volume":"29","author":"S Ganapathy-Kanniappan","year":"2009","unstructured":"Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Vossen JA, Tchernyshyov I, Cole RN, Syed LH, Rao PP, Ota S, Vali M. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. Anticancer Res. 2009;29(12):4909\u201318.","journal-title":"Anticancer Res"},{"key":"1712_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1476-4598-12-152","volume":"12","author":"S Ganapathy-Kanniappan","year":"2013","unstructured":"Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152. https:\/\/doi.org\/10.1186\/1476-4598-12-152.","journal-title":"Mol Cancer"},{"issue":"12","key":"1712_CR6","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.14670\/HH-29.1511","volume":"29","author":"F Baltazar","year":"2014","unstructured":"Baltazar F, Pinheiro C, Morais-Santos F, Azevedo-Silva J, Queiros O, Preto A, Casal M. Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol Histopathol. 2014;29(12):1511\u201324. https:\/\/doi.org\/10.14670\/HH-29.1511.","journal-title":"Histol Histopathol"},{"issue":"2","key":"1712_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1042\/BJ20140921","volume":"467","author":"J Azevedo-Silva","year":"2015","unstructured":"Azevedo-Silva J, Queiros O, Ribeiro A, Baltazar F, Young KH, Pedersen PL, Preto A, Casal M. The cytotoxicity of 3-bromopyruvate in breast cancer cells depends on extracellular pH. Biochem J. 2015;467(2):247\u201358. https:\/\/doi.org\/10.1042\/BJ20140921.","journal-title":"Biochem J"},{"issue":"1","key":"1712_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10863-012-9418-3","volume":"44","author":"O Queiros","year":"2012","unstructured":"Queiros O, Preto A, Pacheco A, Pinheiro C, Azevedo-Silva J, Moreira R, Pedro M, Ko YH, Pedersen PL, Baltazar F, Casal M. Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate. J Bioenerg Biomembr. 2012;44(1):141\u201353. https:\/\/doi.org\/10.1007\/s10863-012-9418-3.","journal-title":"J Bioenerg Biomembr"},{"issue":"1","key":"1712_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/ng.2471","volume":"45","author":"K Birsoy","year":"2013","unstructured":"Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, Hutchins AW, Gultekin Y, Peterson TR, Carette JE, Brummelkamp TR, Clish CB, Sabatini DM. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet. 2013;45(1):104\u20138. https:\/\/doi.org\/10.1038\/ng.2471.","journal-title":"Nat Genet"},{"issue":"3191","key":"1712_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309\u201314.","journal-title":"Science"},{"issue":"4","key":"1712_CR11","first-page":"913","volume":"48","author":"RA Nakashima","year":"1988","unstructured":"Nakashima RA, Paggi MG, Scott LJ, Pedersen PL. Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. Can Res. 1988;48(4):913\u20139.","journal-title":"Can Res"},{"key":"1712_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/bs.acr.2016.07.005","volume":"132","author":"V Te Boekhorst","year":"2016","unstructured":"Te Boekhorst V, Friedl P. Plasticity of cancer cell invasion-mechanisms and implications for therapy. Adv Cancer Res. 2016;132:209\u201364. https:\/\/doi.org\/10.1016\/bs.acr.2016.07.005.","journal-title":"Adv Cancer Res"},{"key":"1712_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.matbio.2015.01.019","volume":"44\u201346","author":"G Shay","year":"2015","unstructured":"Shay G, Lynch CC, Fingleton B. Moving targets: emerging roles for MMPs in cancer progression and metastasis. Matrix Biol. 2015;44\u201346:200\u20136. https:\/\/doi.org\/10.1016\/j.matbio.2015.01.019.","journal-title":"Matrix Biol"},{"issue":"3","key":"1712_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00441-014-1851-7","volume":"355","author":"G Breier","year":"2014","unstructured":"Breier G, Grosser M, Rezaei M. Endothelial cadherins in cancer. Cell Tissue Res. 2014;355(3):523\u20137. https:\/\/doi.org\/10.1007\/s00441-014-1851-7.","journal-title":"Cell Tissue Res"},{"key":"1712_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2015.03.008","author":"WG Jiang","year":"2015","unstructured":"Jiang WG, Sanders AJ, Katoh M, Ungefroren H, Gieseler F, Prince M, Thompson SK, Zollo M, Spano D, Dhawan P, Sliva D, Subbarayan PR, Sarkar M, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Ye L, Helferich WG, Yang X, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Nowsheen S, Pantano F, Santini D. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol. 2015. https:\/\/doi.org\/10.1016\/j.semcancer.2015.03.008.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1712_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10863-012-9425-4","volume":"44","author":"PL Pedersen","year":"2012","unstructured":"Pedersen PL. 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective \u201csmall molecule\u201d anti-cancer agent taken from labside to bedside: introduction to a special issue. J Bioenerg Biomembr. 2012;44(1):1\u20136. https:\/\/doi.org\/10.1007\/s10863-012-9425-4.","journal-title":"J Bioenerg Biomembr"},{"issue":"4","key":"1712_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10863-016-9670-z","volume":"48","author":"J Azevedo-Silva","year":"2016","unstructured":"Azevedo-Silva J, Queiros O, Baltazar F, Ulaszewski S, Goffeau A, Ko YH, Pedersen PL, Preto A, Casal M. The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside. J Bioenerg Biomembr. 2016;48(4):349\u201362. https:\/\/doi.org\/10.1007\/s10863-016-9670-z.","journal-title":"J Bioenerg Biomembr"},{"issue":"3","key":"1712_CR18","first-page":"923","volume":"30","author":"S Ganapathy-Kanniappan","year":"2010","unstructured":"Ganapathy-Kanniappan S, Geschwind JF, Kunjithapatham R, Buijs M, Syed LH, Rao PP, Ota S, Kwak BK, Loffroy R, Vali M. 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. Anticancer Res. 2010;30(3):923\u201335.","journal-title":"Anticancer Res"},{"issue":"14","key":"1712_CR19","first-page":"1681","volume":"122","author":"XH Liu","year":"2009","unstructured":"Liu XH, Zheng XF, Wang YL. Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction. Chin Med J. 2009;122(14):1681\u20135.","journal-title":"Chin Med J"},{"issue":"14","key":"1712_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.lfs.2007.08.016","volume":"81","author":"P Wang","year":"2007","unstructured":"Wang P, Li JC. Trichosanthin-induced specific changes of cytoskeleton configuration were associated with the decreased expression level of actin and tubulin genes in apoptotic Hela cells. Life Sci. 2007;81(14):1130\u201340. https:\/\/doi.org\/10.1016\/j.lfs.2007.08.016.","journal-title":"Life Sci"},{"issue":"37","key":"1712_CR21","doi-asserted-by":"publisher","first-page":"27204","DOI":"10.1074\/jbc.M705161200","volume":"282","author":"X Ling","year":"2007","unstructured":"Ling X, Cheng Q, Black JD, Li F. Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J Biol Chem. 2007;282(37):27204\u201314. https:\/\/doi.org\/10.1074\/jbc.M705161200.","journal-title":"J Biol Chem"},{"issue":"Suppl 4","key":"1712_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1179\/joc.2004.16.Supplement-1.83","volume":"16","author":"L Wilson","year":"2004","unstructured":"Wilson L, Jordan MA. New microtubule\/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies. J Chemother. 2004;16(Suppl 4):83\u20135. https:\/\/doi.org\/10.1179\/joc.2004.16.Supplement-1.83.","journal-title":"J Chemother"},{"key":"1712_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.lfs.2019.03.066","volume":"227","author":"M Pichla","year":"2019","unstructured":"Pichla M, Sroka J, Pienkowska N, Piwowarczyk K, Madeja Z, Bartosz G, Sadowska-Bartosz I. Metastatic prostate cancer cells are highly sensitive to 3-bromopyruvic acid. Life Sci. 2019;227:212\u201323. https:\/\/doi.org\/10.1016\/j.lfs.2019.03.066.","journal-title":"Life Sci"},{"issue":"1\u20132","key":"1712_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11010-015-2478-z","volume":"408","author":"S Aggarwal","year":"2015","unstructured":"Aggarwal S, Singh M, Kumar A, Mukhopadhyay T. SRD5A2 gene expression inhibits cell migration and invasion in prostate cancer cell line via F-actin reorganization. Mol Cell Biochem. 2015;408(1\u20132):15\u201323. https:\/\/doi.org\/10.1007\/s11010-015-2478-z.","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"1712_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jvir.2013.01.013","volume":"24","author":"M Buijs","year":"2013","unstructured":"Buijs M, Wijlemans JW, Kwak BK, Ota S, Geschwind JF. Antiglycolytic therapy combined with an image-guided minimally invasive delivery strategy for the treatment of breast cancer. JVIR. 2013;24(5):737\u201343. https:\/\/doi.org\/10.1016\/j.jvir.2013.01.013.","journal-title":"JVIR"},{"issue":"2","key":"1712_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.yexcr.2004.08.002","volume":"301","author":"T Akahane","year":"2004","unstructured":"Akahane T, Akahane M, Shah A, Connor CM, Thorgeirsson UP. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res. 2004;301(2):158\u201367. https:\/\/doi.org\/10.1016\/j.yexcr.2004.08.002.","journal-title":"Exp Cell Res"},{"issue":"3","key":"1712_CR27","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1042\/BJ20080805","volume":"417","author":"AP Pereira da Silva","year":"2009","unstructured":"Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, Almeida FC, Da Poian AT, Galina A,. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J. 2009;417(3):717\u201326. https:\/\/doi.org\/10.1042\/BJ20080805.","journal-title":"Biochem J"},{"issue":"1","key":"1712_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10863-012-9420-9","volume":"44","author":"Z Tang","year":"2012","unstructured":"Tang Z, Yuan S, Hu Y, Zhang H, Wu W, Zeng Z, Yang J, Yun J, Xu R, Huang P. Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester. J Bioenerg Biomembr. 2012;44(1):117\u201325. https:\/\/doi.org\/10.1007\/s10863-012-9420-9.","journal-title":"J Bioenerg Biomembr"},{"issue":"9","key":"1712_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005758","volume":"13","author":"C Damiani","year":"2017","unstructured":"Damiani C, Colombo R, Gaglio D, Mastroianni F, Pescini D, Westerhoff HV, Mauri G, Vanoni M, Alberghina L. A metabolic core model elucidates how enhanced utilization of glucose and glutamine, with enhanced glutamine-dependent lactate production, promotes cancer cell growth: the WarburQ effect. PLoS Comput Biol. 2017;13(9): e1005758. https:\/\/doi.org\/10.1371\/journal.pcbi.1005758.","journal-title":"PLoS Comput Biol"},{"issue":"49","key":"1712_CR30","doi-asserted-by":"publisher","first-page":"19345","DOI":"10.1073\/pnas.0709747104","volume":"104","author":"RJ DeBerardinis","year":"2007","unstructured":"DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104(49):19345\u201350. https:\/\/doi.org\/10.1073\/pnas.0709747104.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"19","key":"1712_CR31","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1091\/mbc.E15-11-0778","volume":"28","author":"PR Stoddard","year":"2017","unstructured":"Stoddard PR, Williams TA, Garner E, Baum B. Evolution of polymer formation within the actin superfamily. Mol Biol Cell. 2017;28(19):2461\u20139. https:\/\/doi.org\/10.1091\/mbc.E15-11-0778.","journal-title":"Mol Biol Cell"},{"issue":"1","key":"1712_CR32","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/jcp.28965","volume":"235","author":"L Li","year":"2020","unstructured":"Li L, Chen Q, Yu Y, Chen H, Lu M, Huang Y, Li P, Chang H. RKI-1447 suppresses colorectal carcinoma cell growth via disrupting cellular bioenergetics and mitochondrial dynamics. J Cell Physiol. 2020;235(1):254\u201366. https:\/\/doi.org\/10.1002\/jcp.28965.","journal-title":"J Cell Physiol"},{"issue":"3","key":"1712_CR33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.cell.2004.07.011","volume":"118","author":"Y Kang","year":"2004","unstructured":"Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118(3):277\u20139. https:\/\/doi.org\/10.1016\/j.cell.2004.07.011.","journal-title":"Cell"},{"issue":"51","key":"1712_CR34","doi-asserted-by":"publisher","first-page":"7274","DOI":"10.1038\/sj.onc.1203336","volume":"18","author":"KM Hajra","year":"1999","unstructured":"Hajra KM, Ji X, Fearon ER. Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene. 1999;18(51):7274\u20139. https:\/\/doi.org\/10.1038\/sj.onc.1203336.","journal-title":"Oncogene"},{"issue":"9","key":"1712_CR35","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1158\/0008-5472.CAN-09-4439","volume":"70","author":"J Shankar","year":"2010","unstructured":"Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ, Nabi IR. Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Can Res. 2010;70(9):3780\u201390. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4439.","journal-title":"Can Res"},{"issue":"4","key":"1712_CR36","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1091\/mbc.e05-10-0951","volume":"17","author":"W Sheng","year":"2006","unstructured":"Sheng W, Wang G, La Pierre DP, Wen J, Deng Z, Wong CK, Lee DY, Yang BB. Versican mediates mesenchymal-epithelial transition. Mol Biol Cell. 2006;17(4):2009\u201320. https:\/\/doi.org\/10.1091\/mbc.e05-10-0951.","journal-title":"Mol Biol Cell"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01712-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01712-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01712-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T05:17:17Z","timestamp":1658294237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01712-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,18]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1712"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01712-0","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2022,6,18]]},"assertion":[{"value":"13 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that all the ethical standards have been fulfilled.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"121"}}